Infectious background of febrile advanced lung cancer patients who received chemotherapy

Masago,Katsuhiro; Fukuhara,Akiko; Ito,Yutaka; Hatachi,Yukimasa; Irisa,Kaoru; Sakamori,Yuichi; Togashi,Yosuke; Fujita,Shiro; Kim,Young Hak; Mio,Tadashi; Mishima,Michiaki

doi:10.3892/ol_00000150

Infectious background of febrile advanced lung cancer patients who received chemotherapy

Authors:
- Katsuhiro Masago
- Akiko Fukuhara
- Yutaka Ito
- Yukimasa Hatachi
- Kaoru Irisa
- Yuichi Sakamori
- Yosuke Togashi
- Shiro Fujita
- Young Hak Kim
- Tadashi Mio
- Michiaki Mishima
View Affiliations

Affiliations: Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan. masago@kuhp.kyoto-u.ac.jp
Published online on: September 1, 2010 https://doi.org/10.3892/ol_00000150
Pages: 849-853

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The study aimed to determine the diagnostic utility of procalcitonin (PCT) in order to discriminate between infective fever and fever due to inflammation in febrile advanced lung cancer patients treated with cytotoxic chemotherapy. A total of 121 patients with advanced lung cancer, treated with a cytotoxic chemotherapy regimen between September 2007 and September 2008 at Kyoto University Hospital, were recruited. Blood samples were obtained on the first day of the fever. Serum c-reactive protein (CRP) and PCT levels were measured. At least two blood cultures were performed, and sputum was taken for Gram staining and culture. There were 71 episodes in 61 patients in the 12 months of the study, representing 50.4% of our study population. A total of 41 patients (57.7%) were diagnosed with pneumonia using imaging modalities, 6 (8.5%) with bacteremia using blood culture and 4 (5.6%) with urinary tract infections using urine culture. Among the 41 pneumonia cases, culture from sputum revealed pathologic bacteria in 21 (51.2%) and fungal disease in 14 (34.1%) cases. Among the 71 febrile episodes, serum procalcitonin and CRP were measured in 50 episodes. Serum procalcitonin-positive patients showed poor outcomes on antibiotics therapy (Fisher's exact test, p=0.042). Furthermore, serum procalcitonin positivity was able to discriminate infective fever from fever due to inflammation (Chi-square test, p=0.001). We showed the causative organisms of febrile advanced lung cancer patients who received cytotoxic chemotherapy, as well as the possibility of PCT to discriminate infective fever from fever due to inflammation.

View Figures

View References

1	Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American Thoracic Society. Am J Respir Crit Care Med. 171:388–416. 2005. View Article : Google Scholar : PubMed/NCBI
2	Pfister DG, Johnson DH, Azzoli CG, et al: American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 22:330–353. 2004. View Article : Google Scholar : PubMed/NCBI
3	Klastersky J: Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 39(Suppl 1): S32–S37. 2004. View Article : Google Scholar : PubMed/NCBI
4	Jacobs JW, Lund PK, Potts JT Jr, Bell NH and Habener JF: Procalcitonin is a glycoprotein. J Biol Chem. 256:2803–2807. 1981.PubMed/NCBI
5	Le Moullec JM, Jullienne A, Chenais J, et al: The complete sequence of human preprocalcitonin. FEBS Lett. 167:93–97. 1984.
6	Karzai W, Oberhoffer M, Meier-Hellmann A and Reinhart K: Procalcitonin – a new indicator of the systemic response to severe infections. Infection. 25:329–334. 1997.
7	Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med. 153:1711–1725. 1996. View Article : Google Scholar
8	Herpers BL, De Jongh BM, van der Zwaluw K and van Hannen EJ: Real-time PCR assay targets the 23s-5s spacer for direct detection and differentiation of legionella spp. and legionella pneumophila. J Clin Microbiol. 41:4815–4816. 2003. View Article : Google Scholar : PubMed/NCBI
9	Helbig JH, Uldum SA, Bernander S, et al: Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial legionnaires' disease. J Clin Microbiol. 41:838–840. 2003. View Article : Google Scholar : PubMed/NCBI
10	Smith MD, Derrington P, Evans R, et al: Rapid diagnosis of bacteremic pneumococcal infections in adults by using the binax now streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol. 41:2810–2813. 2003. View Article : Google Scholar
11	Finch RG and Woodhead MA: Practical considerations and guidelines for the management of community-acquired pneumonia. Drugs. 55:31–45. 1998. View Article : Google Scholar : PubMed/NCBI
12	Ibrahim EH, Ward S, Sherman G and Kollef MH: A comparative analysis of patients with early-onset vs. late-onset nosocomial pneumonia in the ICU setting. Chest. 117:1434–1442. 2000. View Article : Google Scholar : PubMed/NCBI
13	Kollef MH: The prevention of ventilator-associated pneumonia. N Engl J Med. 340:627–634. 1999. View Article : Google Scholar : PubMed/NCBI
14	Taylor GD, Buchanan-Chell M, Kirkland T, McKenzie M and Wiens R: Bacteremic nosocomial pneumonia. A 7-year experience in one institution. Chest. 108:786–788. 1995.PubMed/NCBI
15	Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J and Bohuon C: High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 341:515–518. 1993. View Article : Google Scholar : PubMed/NCBI
16	Gendrel D, Raymond J, Coste J, et al: Comparison of procalcitonin with c-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J. 18:875–881. 1999. View Article : Google Scholar : PubMed/NCBI
17	Kuse ER, Langefeld I, Jaeger K and Kulpmann WR: Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection. Crit Care Med. 28:555–559. 2000. View Article : Google Scholar : PubMed/NCBI
18	Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P, et al: Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect. 10:628–633. 2004. View Article : Google Scholar : PubMed/NCBI
19	Hambach L, Eder M, Dammann E, et al: Diagnostic value of procalcitonin serum levels in comparison with c-reactive protein in allogeneic stem cell transplantation. Haematologica. 87:643–651. 2002.PubMed/NCBI
20	Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, Anargyrou K, Katsilambros N and Giamarellou H: Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis. 32:1718–1725. 2001. View Article : Google Scholar : PubMed/NCBI
21	Blijlevens NM, Donnelly JP, Meis JF, De Keizer MH and De Pauw BE: Procalcitonin does not discriminate infection from inflammation after allogeneic bone marrow transplantation. Clin Diagn Lab Immunol. 7:889–892. 2000.PubMed/NCBI
22	Ortega M, Rovira M, Filella X, et al: Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation. Br J Haematol. 126:372–376. 2004. View Article : Google Scholar : PubMed/NCBI
23	Prieto B, Llorente E, Gonzalez-Pinto I and Alvarez FV: Plasma procalcitonin measured by time-resolved amplified cryptate emission (trace) in liver transplant patients. A prognosis marker of early infectious and non-infectious postoperative complications. Clin Chem Lab Med. 46:660–666. 2008. View Article : Google Scholar